Skip to main content
HairCited

Telogen Effluvium: A Review.

Shashikant Malkud
Review Journal of clinical and diagnostic research : JCDR 2015 190 citas
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D26500992'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo de estudio
Review
Intervención
Telogen Effluvium: A Review.
Comparador
Placebo
Dirección del efecto
Neutral
Riesgo de sesgo
Unclear

Abstract

Telogen effluvium was first described by Kligman in 1961. It is a most common cause of diffuse hair loss. Women with telogen effluvium more frequently present to dermatologist. A wide variety of potential triggers have been implicated in the pathogenesis of telogen effluvium. Diffuse shedding of telogen hair are seen after 3-4 months of triggering event. The observation of increased telogen hair shedding does not infer a cause. Establishing aetiology of telogen effluvium requires elicitation of relevant history and appropriate laboratory investigations to exclude endocrine, nutritional and autoimmune disorders.

Used In Evidence Reviews

Similar Papers